Pharma Jobs: Sales Shake Up at IHolland & New CFO at Sinovac
We begin this week with news from the UK and tablet tooling company IHolland has appointed former Business Manager and Sales Director at Linx Printing, Andrew Priestley, as Sales and Marketing Director.
According to I Holland Managing Director Chris Prideaux: “Andrew’s appointment will be central to increasing our sales and marketing activities worldwide. Andrew is highly qualified and experienced and we look forward to working with him.”
And in-Pharmatechnologist.com caught up with IHolland at this year’s Interphex in New York. Watch the interview here.
Next to China, and vaccine manufacturer Sinovac – who recently received updated cGMP accreditation from the CFDA – has announced Nan Wang, currently Vice President, has been appointed as Chief Financial Officer.
Wang has been with the company since 2001 and “has served as a valuable member of Sinovac's senior management team and developed a wealth of experience in the vaccine sector, communications with investors, fundraising, and financial management,” according to CEO Weidong Yin.
To San Diego now, and MEI Pharma has added Dr. Nick Glover to its Board of Directors.
Most recently President and Chief Executive Officer of YM BioSciences - an oncology drug development company acquired by Gilead Sciences for $510 million earlier this year – “Dr. Glover is a natural fit to round out [MEI Pharma’s] Board of Directors, adding a wealth of relevant strategic and operational knowledge,” said CEO Dr. Daniel Gold.
Next we have news from biopharmaceutical company PTC Therapeutics who has announced former Managing Director, Health Care Investment Banking at Credit Suisse, Shane Kovacs, as Chief Financial Officer.
“We are excited to welcome Shane as a member of our senior management team,” said CEO Dr. Stuart Peltz. “His extensive background in both the finance and biotechnology sectors makes him a valuable addition to PTC.”
And finally this week there is news from regenerative medicine company Histogenics who has appointed Peter Greenleaf as its new CEO.
Greenleaf most recently served as President of MedImmune, the biologics arm of AstraZeneca, and before this in his twenty year career he has held senior roles at Centocor, Boehringer Mannheim and U.S. Healthcare.
“Peter’s expertise in growing smaller biotech companies into industry leaders will be critical as we work to move NeoCart [a personalized hyaline-like cartilage tissue implant for patients using their own cells] through pivotal trials and ultimately toward launch and commercialization,” said Histogenics Chairman Garheng Kong.
